<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="/Users/pm286/workspace/tigr2ess/osanctum/PMC6023537/results/search/drugs/results.xml">
  <result pre="comparator drug. A dose of 175 µg/kg/day [ 21] of" exact="sildenafil" post="dissolved in distilled water was administered orally. Monocrotaline (MCT;"/>
  <result pre="SIL: Rats were injected MCT (50 mg/kg; sc) followed by" exact="sildenafil" post="175 µg/kg/day orally once daily started from day 29"/>
  <result pre="to confirm development of PH before and after OS or" exact="sildenafil" post="administration (day 29 to day 42), while control and"/>
  <result pre="was significantly decreased by OS ( p &amp;lt; 0.05). However," exact="sildenafil" post="did not cause significant change ( Figure 1A). Lung"/>
  <result pre="administered rats as compared to control ( Figure 1B,C). Moreover," exact="sildenafil" post="( p &amp;lt; 0.001), and OS ( p &amp;lt;"/>
  <result pre="pressures (RVeDP) at 42 days ( Figure 2A,B). OS and" exact="sildenafil" post="significantly reduced RVSP in MCT administered rats which were"/>
  <result pre="MCT administered rats which were comparable to control while, only" exact="sildenafil" post="reduced RVeDP caused by MCT ( Figure 2B). There"/>
  <result pre="p &amp;lt; 0.05) caused by MCT ( Figure 3A,B). However," exact="sildenafil" post="cured only the RVoTD/AoD ratio (0.59 ± 0.02 vs."/>
  <result pre="27.36 ± 3.0 mg/mg protein; p &amp;lt; 0.001). OS and" exact="sildenafil" post="administration did not cause significant difference in lung reduced"/>
  <result pre="10.8 U/mg protein) as compared with control rats. OS and" exact="sildenafil" post="treatment did not alleviate the decrease in lung SOD"/>
  <result pre="Nox-1 caused by MCT administration ( p &amp;lt; 0.001). However," exact="sildenafil" post="did not significantly decrease protein expression of Nox-1 caused"/>
  <result pre="of apoptotic changes which was preserved significantly by OS and" exact="sildenafil" post="( p &amp;lt; 0.001) administration ( Figure 5B). 4."/>
  <result pre="reported in earlier studies [ 44, 45, 46]. OS and" exact="sildenafil" post="were started from day 29 to day 42. At"/>
  <result pre="PH [ 44, 45]. It was observed that OS and" exact="sildenafil" post="significantly ameliorated the raised RVSP and RV hypertrophy caused"/>
  <result pre="49]. In our study, it has been observed that the" exact="sildenafil" post="and OS decreased the thickness of smaller arterioles (&amp;lt;100"/>
  <result pre="feature of PH. Moreover, it has been also reported that" exact="sildenafil" post="prevented pulmonary arterial remodeling in rats and this effect"/>
  <result pre="51]. This was also significantly ameliorated with OS treatment, but" exact="sildenafil" post="did not cause any significant difference. It has been"/>
  <result pre="RV hypertrophy which leads to an increase in RVSP, while" exact="sildenafil" post="had a curative effect on RV hypertrophy (RVH). OS"/>
  <result pre="of OS might be due to its antioxidant property. However," exact="sildenafil" post="only decreased the lung TBARS levels while OS and"/>
  <result pre="sildenafil only decreased the lung TBARS levels while OS and" exact="sildenafil" post="did not cause significant difference in lung SOD levels"/>
  <result pre="Harada T. Kikuzuki R. Yamawaki H. Hara Y. Effects of" exact="telmisartan" post="on right ventricular remodeling induced by monocrotaline in rats"/>
  <result pre="P.M. Johns R.A. Attenuation of chronic hypoxic pulmonary hypertension by" exact="simvastatin" post="Am. J. Physiol. Heart Circ. Physiol. 2003 285 H938"/>
  <result pre="Sonoda H. Ito K.M. Ikeda M. Ito K. Evaluation of" exact="olmesartan" post="medoxomil in the rat monocrotaline model of pulmonary hypertension"/>
  <result pre="W. Jr. Shaddy R.E. Growth factor expression and effects of" exact="amrinone" post="in monocrotaline-induced pulmonary hypertension in rats Biochem. Mol. Med."/>
 </snippets>
</snippetsTree>
